Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its 45% owned joint venture, Sapu Nano, has identified a High-RICTOR/Low-RPTOR molecular signature that predicts tumor sensitivity to Sapu003, the company's intravenous Deciparticle formulation of everolimus. The biomarker framework, to be presented at the 2025 San Antonio Breast Cancer Symposium, represents the first prospective selection strategy for IV everolimus and is based on analysis of more than 9,000 tumor samples across 20 cancer types.
Data from the research indicates that mTORC2-dominant tumors exhibit heightened mTOR dependency and predicted sensitivity to Sapu003. These tumor types include HR+/HER2- breast cancer, lung adenocarcinoma, gastric cancer, renal cancer, ovarian cancer, acute myeloid leukemia (AML), and T-cell malignancies. The identification of this biomarker signature could enable clinicians to select patients most likely to benefit from Sapu003 treatment, potentially improving therapeutic outcomes while reducing unnecessary treatment for patients unlikely to respond.
Sapu003 represents an advancement over oral everolimus formulations by overcoming several limitations through higher tissue penetration, reduced gastrointestinal accumulation, and preserved metabolic specificity. This intravenous delivery method may offer improved efficacy and reduced side effects compared to existing oral mTOR inhibitors. The development of a predictive biomarker for this therapy addresses a critical need in precision oncology, where identifying which patients will respond to specific treatments remains a significant challenge.
The research findings will be presented at the upcoming 2025 San Antonio Breast Cancer Symposium, a premier scientific meeting for breast cancer research. Additional information about Oncotelic Therapeutics is available through the company's newsroom at https://ibn.fm/OTLC. Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications.
The identification of this biomarker signature has implications for cancer treatment across multiple tumor types. By enabling more targeted use of Sapu003, healthcare providers could potentially improve patient outcomes while optimizing healthcare resources. The research represents progress toward personalized medicine approaches in oncology, where treatments are increasingly tailored to individual patient characteristics and tumor biology. For the pharmaceutical industry, successful validation of this biomarker could establish a new paradigm for patient selection in mTOR inhibitor therapy and influence development strategies for similar targeted cancer treatments.
